Pre-IPO MicroTech Medical (Hangzhou) - The Main Products, the Business and the Challenges

Pre-IPO Neusoft Medical Systems - Promising Market but Full of Challenges

LinkDoc Technology (LDOC.US) - Here Are the Concerns

LinkDoc (零氪科技) Pre-IPO - Peer Comparison - A Niche that Doesn’t Give a Clear Advantage

LinkDoc (零氪科技) Pre-IPO - Thoughts on Valuation

Gravity Works As WeWork Doesn't; Now Plan B

Bifurcated Chinese Express Market Developing

APAC IPOs & Placements

Zhen Zhou, Toh

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

<div>
<div><div><div class="content-highlight">
<h2>Error Corrigendum</h2>
<p><em>A previous version of this insight, titled "LinkDoc (零氪科技) IPO - Reasonably Priced for the Long Haul", contained serious error assuming a much smaller market cap based on the wrong number of outstanding shares/ADS for LinkDoc. It led us to believe that the IPO was priced cheaply.</em></p>
<p><em>In this note, it will be updated with the correct figures which will change our view from our previous note.</em></p>
<p><em>Our sincere apologies for the error. Do feel free to reach out to us for any clarifications.</em></p>
</div></div></div>
<p><a href="https://www.smartkarma.com/entities/linkdoc-technology-limited" target="_blank" data-smartkarma-citation="entities:33499:1" rel="noopener">LinkDoc (LDOC US)</a> is looking to raise up to US$211m in its U.S. IPO.</p>
</div><div><p>LinkDoc is a data-driven and AI-enabled healthcare technology company. The company operates data-driven digital infrastructures to serve different stakeholders in the healthcare ecosystem. The company has a focus on oncology with its patient care centres providing oncology patients with continuous care.</p></div><div><p>In this note, we will look at deal dynamics, assumptions, and share our final thoughts on valuation.</p></div><div><p>We have previously covered the IPO in: </p></div><div><ul style="list-style-type: disc;">
<li>
<a href="https://www.smartkarma.com/insights/linkdoc-pre-ipo-intricately-embedded-in-the-oncology-industry" target="_blank" data-smartkarma-citation="insights:53324" rel="noopener">LinkDoc (零氪科技) Pre-IPO - Intricately Embedded in the Oncology Industry</a> </li>
<li>
<a href="https://www.smartkarma.com/insights/linkdoc-pre-ipo-peer-comparison-a-niche-that-doesn-t-give-a-clear-advantage" target="_blank" data-smartkarma-citation="insights:53723" rel="noopener">LinkDoc (零氪科技) Pre-IPO - Peer Comparison - A Niche that Doesn’t Give a Clear Advantage</a> </li>
<li>
<a href="https://www.smartkarma.com/insights/linkdoc-pre-ipo-thoughts-on-valuation" target="_blank" data-smartkarma-citation="insights:53787" rel="noopener">LinkDoc (零氪科技) Pre-IPO - Thoughts on Valuation</a> </li>
</ul></div>



Error Corrigendum
A previous version of this insight, titled "LinkDoc (零氪科技) IPO - Reasonably Priced for the Long Haul", contained serious error assuming a much smaller market cap based on the wrong number of outstanding shares/ADS for LinkDoc. It led us to believe that the IPO was priced cheaply.
In this note, it will be updated with the correct figures which will change our view from our previous note.
Our sincere apologies for the error. Do feel free to reach out to us for any clarifications.

LinkDoc (LDOC US) is looking to raise up to US$211m in its U.S. IPO.
LinkDoc is a data-driven and AI-enabled healthcare technology company. The company operates data-driven digital infrastructures to serve different stakeholders in the healthcare ecosystem. The company has a focus on oncology with its patient care centres providing oncology patients with continuous care.In this note, we will look at deal dynamics, assumptions, and share our final thoughts on valuation.We have previously covered the IPO in: 

LinkDoc (零氪科技) Pre-IPO - Intricately Embedded in the Oncology Industry 

LinkDoc (零氪科技) Pre-IPO - Peer Comparison - A Niche that Doesn’t Give a Clear Advantage 

LinkDoc (零氪科技) Pre-IPO - Thoughts on Valuation 


LinkDoc (零氪科技) IPO - Revised Thoughts on Valuation